Generex Biotechnology Corp. (GNBT)
Generex Biotechnology Corporation engages in the research, development, and commercialization of drug delivery systems and technologies for metabolic and immunological diseases. It develops a proprietary platform technology for the delivery of drugs into the human body through the oral cavity. The company’s primary product, Oral-lyn is an insulin spray formulation used for the treatment of Type-1 and Type-2 diabetes. It also develops Glucose RapidSpray that delivers glucose through a pump spray to the mouth, as well as morphine and fentanyl by oral formulation and injection for the treatment of moderate to severe breakthrough and postoperative pain. In addition, the...
Watch the video to learn about the probability of Generex Biotechnology Corp. (GNBT) Chart Signal as of Jun 19 2013
Hotstocked Precision will calculate the probabilities of Generex Biotechnology Corp. (GNBT)
To see the headquarters in Google Street View &trade, drag this yellow guy: 
over to the red pointer: 
Contact Information:
| Business Address: | - |
| Mailing Address: | 33 HARBOUR SQ STE 202 TORONTO ONTARIO CA A1 M5J 2G2 Business Address 33 HARBOUR SQ STE 202 TORONTO ONTARIO CANADA A1 M5J 2G2 4163642551 |
| Phone: | 416-364-2551 |
| Fax: | 416-364-9363 |
| Website: | http://www.generex.com |
Company Details:
| Symbol: | GNBT |
| SIC: | - |
| State location: | A1 |
| Sector: | - |
| State of Inc: | DE |
| Employees: | 43 |
| Type: | OTCBB |
Key executives:
| Name | Age | Position |
|---|---|---|
| Anna E. Gluskin | 62 | Chairman, Chief Exec. Officer and Pres |
| Eric Von Hofe Ph.D. | - | Pres of Antigen Express |
| Gerald Bernstein M.D. | 80 | VP of Medical Affairs |
| Mark Fletcher Esq. | 47 | Exec. VP and Gen. Counsel |
| Rose C. Perri | 46 | Chief Operating Officer, Chief Financial Officer, Principal Accounting Officer, Sec., Treasurer |
Watch the video to learn about the probability of Generex Biotechnology Corp. (GNBT) Chart Signal as of Jun 19 2013
This free program will calculate the probabilities of Generex Biotechnology Corp. (GNBT) stock chart
| Rating: |
|
Platform: | Win/Mac |
| Price: | FREE | Version: | 1.1 |
| Size: | 656KB | Downloads: |
Generex Biotechnology Corp.(OTCMKTS:GNBT) On Its Way To Recovery Jun 3, 2013
After the slump they suffered back on May 24 Generex Biotechnology Corp. (OTCMKTS:GNBT) finally recovered some of the lost ground. A couple of tumultuous sessions followed after the fall to 3 cents per share. Finally last Friday the ticker recovered some lost ground when it surged by more than 21% to reach $0.36. Interest in the stock was also significant with 21 million shares traded at the end of the day.read more
Generex Biotechnology Corp. (OTCMKTS:GNBT) Ends the Week in the Red May 28, 2013
Just before the weekend Generex Biotechnology Corp. (OTCMKTS:GNBT) slid down towards the bottom of the stock chart with nearly 20% to close at $0.031. Investors decided that the price levels are high enough and cashed in their holdings resulting in traded volume of more than 15 million shares. This came hot on the heels of several positive session that brought the ticker 30% up to as high as $0.0386.read more
Generex Biotechnology Corporation (OTC:GNBT) Cools Down After Spike Feb 5, 2013
Yesterday Generex Biotechnology Corporation (OTC:GNBT) failed to restrain the slide it went into, following a spike last Thursday. The stock slipped another 21%, closing down in double-digits for the third day in a row, and settled at $0.031.read more
Generex Biotechnology, Inc. (OTC:GNBT) Spikes on Therapies Outlook Jan 31, 2013
Penny stock circles see a lot of promise in the field of biotechnologies, and news in this area help lift tickers dramatically. Gererex Biotechnologies, Inc. (OTC:GNBT) spiked by 59.5% on Wednesday as the company released material news on its business. Our database still has not registered a pump for this ticker, so the rise is mostly due to messages from the company.read more
Generex Biotechnology Corp. (OTC:GNBT) Recovers Lost Ground Jan 18, 2013
Most biotechnological companies run a race against time, with a long development period and uncertainty until the therapies or products achieve lasting marketing success. This is the case of Generex Biotechnology Corp. (OTC:GNBT), a company that claims it is viable for NASDAQ listing, but still has too many products in preliminary trial.read more
New product tease rewards TEGY traders with a 45% gain Dec 16, 2010, 15:52
New product tease rewards TEGY traders with a 45% gain
TEGY Adds Some New Power Technologies to its Platform, and the Market Applauds!
Good Afternoon!
We knew that Transact Energy Corp. (TEGY) tends to make large and sudden moves, but this morning's 45% bounce was a lot more satisfying than we expected!
After TEGY announced that it's talking about licensing read more
| Promoter: BeaconEquity.com | Paying Party: Unknown | Max Profit: Pending | Gain at close: Pending |
| Stock: GNBT | Compensation: $50,000 | Avg $ Volume for Period: UNKNOWN | |
=?WINDOWS-1252?Q?GNBT_is_being_accumulated_ Dec 16, 2010, 09:41
GNBT is being accumulated – FAST!
Trade Alert: Generex Biotechnology Corp. (GNBT)
GNBT is 83% Off Recent Highs – But Now Reversing Course as FDA Approval is Sought!
Good Morning Hideout Trader!
The future of Generex Biotechnology Corporation (GNBT) which develops drug delivery systems and technologies is looking mighty bright again!
The read more
| Promoter: Stock Hideout | Paying Party: Unknown | Max Profit: Pending | Gain at close: Pending |
| Stock: GNBT | Compensation: $90,000 BlueWave Advisors, LLC owns seventy five percent of the outstanding membership interests of StockHideout LLC. Stock_Analyzer owns twenty five percent of the outstanding membership interests of StockHideout, LLC. BlueWave Advisors has been compensated ninety thousand dollars from Emerging Equity Advisors, Inc. - non-controlling 3rd party sh | Avg $ Volume for Period: UNKNOWN | |
PennyStockProphet - GNBT - Thursday! Dec 16, 2010, 09:20
PSP Members, I've got a bio-tech pick for us today that's picking up enormous momentum as it appears ready to bounce of it's 52-week low! This is a NASDAQ quality company currently trading at penny stock prices, and it's time to take advantage of it! The company's current 10-day trading average is over 1.3 Million shares per day and climbing! Volume has been picking up every day since Monday, and the company just announced yesterday a new patent read more
| Promoter: Penny Stock Prophet | Paying Party: UNKNOWN | Max Profit: Pending | Gain at close: Pending |
| Stock: GNBT | Compensation: Unknown compensation | Avg $ Volume for Period: UNKNOWN | |